Are Dezawa Muse Cells FDA Approved? The Real Regulatory Status

Starting with the plain facts

The question of FDA approval is the most important compliance question a patient or attorney can ask about any regenerative therapy. The answer for Dezawa Muse cells is unambiguous: as of May 2026, no Dezawa Muse cell product holds FDA approval, FDA clearance, or an active Investigational New Drug (IND) application in the United States for any clinical indication.

That single fact needs to be stated at the outset, without qualifications that soften it, because patients deserve accurate information before making any treatment decision. The rest of this article explains the regulatory landscape in full - because the full picture is more nuanced than a binary approved/not-approved frame suggests, and that nuance matters for understanding what reputable U.S. physicians can and cannot legally offer.

What FDA approval actually means

The phrase "FDA approved" has a specific legal meaning. For a drug or biologic - which is the category allogeneic cell therapies fall into - FDA approval means the agency has reviewed clinical evidence from Phase I, II, and III trials, confirmed the product's manufacturing process meets current Good Manufacturing Practice (cGMP) standards, and granted a Biologics License Application (BLA) or New Drug Application (NDA) authorizing the product for a specific indication in a specific patient population.

As of May 2026, the FDA has approved a limited number of cell and gene therapy products. These include treatments for certain leukemias (CAR-T therapies such as Kymriah and Yescarta), a gene-based stem cell therapy for Wiskott-Aldrich syndrome approved in December 2025, and Omisirge for severe aplastic anemia. None involve Dezawa Muse cells.

What "FDA approved" does not mean:

• It does not mean "endorsed by FDA as the best option" - approved means adequate evidence of safety and efficacy for a defined use.
• It does not mean "everything else is illegal" - as discussed below, other legal frameworks exist for cell therapies.
• It does not mean "FDA unapproved equals dangerous" - many research-stage therapies have favorable safety profiles before full approval is established.

Why FDA approval takes so long for cell therapies

The approval timeline for cell therapies is longer and more expensive than for conventional pharmaceuticals. The reasons are structural, not bureaucratic:

Manufacturing complexity. A pill is the same pill from batch to batch. A living cell product requires proving, across every lot, that the cells have consistent identity (verified by surface markers like SSEA-3), potency (they do what they're claimed to do), purity (no contaminating cell populations), and sterility. This manufacturing validation is technically demanding and expensive at scale.

Three-phase clinical trial requirement. Before an FDA BLA review can begin, a sponsor must complete Phase I (safety, dosing), Phase II (efficacy signals, dose refinement), and Phase III (large-scale, typically randomized controlled comparison against standard of care). For rare or severe conditions, some pathways allow approval after Phase II, but Phase III data is the standard for broad indications.

Trial design for living cells. Designing a placebo-controlled, blinded clinical trial for an infused cell therapy presents real methodological challenges - including how to control for the procedural aspects of infusion, long-term follow-up requirements for novel biological mechanisms, and the cost of manufacturing sufficient clinical-grade product to power a Phase III trial.

The total cost for a biologic from IND to BLA approval averages $500 million or more and typically spans 10 to 15 years. Dezawa Muse cells, discovered in 2010, are approximately 15 years into research. The clinical trial program in Japan is still completing Phase II for several indications. Full U.S. FDA approval would require an entirely separate regulatory pathway initiated by a U.S. IND application.

The HCT/P framework: what it is and why it matters

Not every cell-based product requires FDA premarket approval before a U.S. physician can offer it. The HCT/P framework - Human Cells, Tissues, and Cellular and Tissue-Based Products - is the regulatory structure that governs this distinction. It is codified in Title 21 of the Code of Federal Regulations (CFR), Part 1271.

Under 21 CFR 1271.10, a cell or tissue product can be regulated solely under Section 361 of the Public Health Service Act (and thus exempt from premarket approval) if it meets all four of these criteria:

1. Minimal manipulation - the processing does not alter the relevant biological characteristics of the cells or tissue.
2. Homologous use - the product performs the same basic function in the recipient as it did in the donor.
3. No combination with drugs or devices - except for water, crystalloids, or sterilizing/preserving/storage agents.
4. No systemic effect dependence - the product does not depend on the metabolic activity of living cells for its primary function, unless it is for autologous use, use in first- or second-degree relatives, or reproductive use.

Products meeting all four criteria are called 361 HCT/Ps. They require FDA establishment registration and compliance with current Good Tissue Practice (cGTP) but do not require a BLA, IND, or premarket approval.

Products that fail to meet any one of the four criteria are 351 HCT/Ps - regulated as drugs or biologics requiring full FDA approval or an active IND.

Why Dezawa Muse cells do not fit the 361 HCT/P exemption

The 361 pathway was designed for minimally processed tissue used in ways that closely mirror that tissue's natural role - for example, a preserved cornea used in corneal transplant, or minimally processed bone used to fill a bone defect. It was not designed for allogeneic pluripotent cells administered intravenously to produce systemic regenerative effects across multiple organ systems.

Dezawa Muse cells as described in published research fail the 361 exemption for at least two of the four criteria:

• Minimal manipulation: SSEA-3-based immunoselection to isolate a 1-to-4-percent subpopulation from a mesenchymal stem cell population alters the composition of the original tissue in a way that likely exceeds "minimal manipulation" as defined in FDA guidance (July 2020).
• Homologous use: Administering allogeneic Muse cells intravenously to home to injury sites and differentiate into tissue types not originally found at the administration site is not homologous use of the donor tissue.

This classification is significant. It means that administering allogeneic Dezawa Muse cells outside of a formal clinical trial in the United States, without an active IND, would likely constitute administering an unapproved biologic - regardless of the safety profile of the cells themselves.

This is the same legal territory that has led to FDA warning letters and enforcement actions against stem cell clinics in 2024 and 2025, including letters to Chara Biologics (January 2025), BioStem Life Sciences (January 2025), and Cellebration LLC (September 2025). In October 2025, the U.S. Supreme Court declined to revisit a Ninth Circuit ruling confirming the FDA's authority to regulate allogeneic cell products as biologics requiring premarket approval.

These products have not been evaluated by the U.S. FDA and are not intended to diagnose, treat, cure, or prevent any disease. Patients considering any cell therapy should verify - before treatment - exactly which regulatory framework applies to the product being offered.

The RMAT pathway: an accelerated route that doesn't yet apply

The 21st Century Cures Act, enacted in December 2016, created a specialized designation called Regenerative Medicine Advanced Therapy (RMAT). RMAT was designed to accelerate the development of promising cell therapies for serious or life-threatening conditions where preliminary clinical evidence suggests meaningful benefit.

A product holding RMAT designation receives intensive FDA guidance during development, rolling BLA review, and eligibility for accelerated approval based on surrogate endpoints. As of 2026, over 130 RMAT designations have been granted by the FDA's Center for Biologics Evaluation and Research (CBER).

Dezawa Muse cells do not currently hold RMAT designation. Receiving this designation would require a U.S. sponsor to file a request supported by preliminary clinical evidence from a U.S.-registered IND. The Japanese clinical trial data from Life Science Institute (a Mitsubishi Chemical Group subsidiary) could in principle support such an application - but no public record of a U.S. RMAT application for a Muse cell product exists as of this writing.

RMAT designation, if and when granted, would accelerate the development timeline, not substitute for it. A product with RMAT designation is still an investigational product. It has not been evaluated by the U.S. FDA for safety and effectiveness in the sense that full approval implies.

How Japan's regulatory pathway differs from the FDA

Japan has a distinct regulatory framework for regenerative medicine products, governed primarily by the Act on the Safety of Regenerative Medicine (ASRM) and the Pharmaceutical and Medical Device Act (PMDA). These laws were substantially reformed in 2014 specifically to create faster access pathways for regenerative therapies.

The key differences from the U.S. FDA approach:

Japan's conditional approval pathway allows a product to reach market based on Phase II evidence, with final approval contingent on collecting post-market effectiveness data for seven years. This pathway was created to give Japanese patients earlier access to promising regenerative therapies while maintaining ongoing evidence requirements.

Dezawa Muse cells in the CL2020 formulation (manufactured by Life Science Institute) are advancing through clinical trials in Japan under the Sakigake fast-track system for multiple indications including acute myocardial infarction (heart attack), ischemic stroke, spinal cord injury, and epidermolysis bullosa. Phase II trials have been conducted; Phase III programs are ongoing for certain indications.

None of this constitutes U.S. FDA approval or FDA clearance. Japan's conditional approval for a specific indication, if and when granted, means the product has met Japan's regulatory standard for that indication - not the FDA's. The two agencies apply different evidentiary requirements and different post-market conditions. A patient or physician relying on Japanese regulatory status as a proxy for FDA approval is drawing an incorrect equivalence.

What "physician discretion" and "off-label use" do and do not mean

A common framing in the regenerative medicine industry holds that physicians have broad discretion to offer treatments that are not FDA approved, based on the principle that the FDA regulates products, not the practice of medicine. This framing is accurate in a limited sense and dangerously misleading in a broader one.

Off-label prescribing is legal in the United States. A physician can prescribe an FDA-approved drug for an indication not listed on its FDA-approved label. This is common practice in oncology, psychiatry, and pediatric medicine. The key word is "FDA-approved drug." Off-label prescribing applies to products that already have FDA approval - it does not authorize administering products that have never received any FDA approval.

The Ninth Circuit Court of Appeals confirmed in 2024 that physicians cannot classify distribution of unapproved biological products as exempt from FDA oversight simply by characterizing it as a professional medical service. The court affirmed the FDA's authority to regulate allogeneic cell products administered by physicians as the biologics they are. The U.S. Supreme Court declined to reconsider this ruling in October 2025.

What this means practically: a U.S. physician who offers allogeneic Dezawa Muse cell infusions outside the 361 HCT/P framework and without an active IND is not operating under physician discretion in the legal sense. They are administering an unapproved biologic.

These products have not been evaluated by the U.S. FDA and are not intended to diagnose, treat, cure, or prevent any disease. Any clinic offering Dezawa Muse cell therapy in the U.S. should be able to clearly state the specific regulatory basis under which they operate.

What transparency looks like from a reputable program

A physician offering any cell-based therapy under a legitimate regulatory framework should be able to provide clear answers to each of the following without hesitation:

• The exact regulatory classification of the product being administered (361 HCT/P, 351 IND, or other) and the specific basis for that classification.
• The manufacturer's name, the certificate of analysis for the batch to be administered, and SSEA-3+ verification for any product claiming to be authentic Dezawa Muse cells.
• Whether the physician has reviewed the published Phase II clinical trial data from Japan, and what their clinical assessment of that data is for the patient's specific condition.
• A clear statement that this therapy has not been evaluated by the U.S. FDA and is not intended to diagnose, treat, cure, or prevent any disease, delivered verbally and in writing before consent is signed.
• What adverse event monitoring and reporting procedures are in place, and to whom adverse events would be reported.

Opacity on any of these points is a material red flag. The regulatory landscape for regenerative medicine is genuinely complex, and good physicians working in this space know that complexity and communicate it clearly. Clinics that minimize the regulatory picture or imply equivalence between Japanese clinical progress and U.S. approval are not serving patients accurately.

Where Dezawa Muse cells actually stand today

Dezawa Muse cell research has produced more than 120 peer-reviewed publications since the original 2010 discovery by Professor Mari Dezawa at Tohoku University. Phase II clinical trials have been completed in Japan for cardiac indications with data suggesting meaningful improvements in cardiac function. The CL2020 product from Life Science Institute is advancing through the Japanese regulatory system under the Sakigake fast-track for multiple indications.

The preclinical safety profile is well-characterized: no teratoma formation in long-term animal studies, stable karyotype in extended culture, immune privilege through HLA-G and IDO expression, and no documented requirement for immunosuppression in human trial participants. Read the full safety review here.

That body of evidence is meaningful. It is also not FDA approval, and it does not substitute for the clinical trial standard the FDA requires before authorizing a product for U.S. use in a specific indication.

For patients considering regenerative medicine programs, the practical takeaway is this: the absence of FDA approval does not necessarily mean a therapy is ineffective or dangerous - but it does mean the patient and physician are operating with less evidence certainty than FDA approval would provide, and the legal and ethical framework for offering that therapy must be explicitly understood and followed. These products have not been evaluated by the U.S. FDA and are not intended to diagnose, treat, cure, or prevent any disease.